1.77
+1.14%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About enGene Holdings
From its filings with the US Securities and Exchange Commission
enGene Holdings is based in Saint-Laurent and is incorporated in Canada (Federal Level). Its shares trade on Nasdaq under the ticker ENGN. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 October 2025, it reported a net loss of $117.3m. At that date it held total assets of $221.5m and shareholders' equity of $167.7m.
Forbion European Acquisition Corporation (“FEAC”) was a special purpose acquisition company (“SPAC”), incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the “Closing Date”), the Company, FEAC, and enGene Inc., a subsidiary of the Company, consummated the merger (the “Reverse Recapitalization” or the “Business Combination”) pursuant to a business combination agreement, dated as of May 16, 2023 (the “Merger Agreement”).
As a result of the Reverse Recapitalization, the Company became a publicly traded company and listed its Common Shares and Warrants on the Nasdaq Global Market under the symbols “ENGN” and “ENGNW,” respectively, commencing trading on November 1, 2023, with enGene Inc. continuing the existing business operations.
We are a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). We are developing non-viral genetic medicines based on our novel and proprietary dually derived chitosan, or “DDX”, gene delivery platform, which allows localized delivery of complex genetic cargos directly to mucosal tissues and other organs.
Quoted from its 10-K, filed 22 Dec 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Dec 2021
- Employees
- 81
- Head office
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT
- Incorporated in
- Z4
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Richard GlickmanIndependent Chairman of the Board, since 2023$208,486
- Mr. Ronald CooperChief Executive Officer, President and Director, since 2024$8.4m
- Mr. Ryan DawsChief Financial Officer and Head - Business Development
- Ms. Joan ConnollyChief Technology Officer
- Dr. Anthony CheungChief Scientific Officer, since 2024
- Mr. Matthew BoydChief Regulatory Officer
- Ms. Jill BuckChief Development Officer
- Dr. Katherine ChanExecutive Director - Urology Clinical Lead
- Dr. Alexander NicholsChief Strategy and Operations Officer$969,950
- Ms. Amy PottChief Global Commercialization Officer
- Dr. Hussein SweitiChief Medical Officer
- Mr. Lee GiguereChief Legal Officer and Corporate Secretary$3.3m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- enGene Inc. develops non-viral gene therapies using DDX platform for mucosal tissues.
- DDX platform offers high payload flexibility for DNA and RNA therapies.
- EG-70 targets BCG-resistant NMIBC with carcinoma in situ (CIS) treatment.
Weaknesses
- Company employs only 81 full-time employees in Biotechnology sector.
- enGene Holdings Inc. is a holding company with limited operational presence.
- Preclinical results show effectiveness in animal models but not yet in humans.
Opportunities
- EG-70 could address unmet needs in BCG-resistant bladder cancer treatments.
- DDX platform may expand to lung and gastrointestinal tract applications.
- Biotechnology sector growth in Health Care industry offers market potential.
Threats
- Biotechnology industry faces regulatory hurdles for gene therapy approvals.
- Competition in Health Care sector for non-viral gene therapy solutions.
- Clinical trials for EG-70 may face delays or failures in human studies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.